From the Government of Saskatchewan
July 19, 2022 | 9:23 am
Saskatchewan expands Trikafta, cystic fibrosis (CF) drug. Starting August 1, Trikafta will be available to CF patients six years of age and older who meet the medical criteria.
“We are pleased to be able to expand this treatment for children in Saskatchewan with cystic fibrosis,” said Health Minister Paul Merriman. “We know that Trikafta has been shown to improve patients’ quality of life, and this expanded coverage will help children with CF and their families for years to come.”
Trikafta targets specific genetic mutations that cause CF; this mutation affects approximately 90 percent of CF patients.
“Today’s news will change the trajectory of the disease and the future for many children in Saskatchewan living with cystic fibrosis,” said Kelly Grover, president and CEO of Cystic Fibrosis Canada. “Saskatchewan was one of the first provinces to fund the drug for those 12 and over last year and today continued to recognize the extraordinary, transformative value of Trikafta by expanding Trikafta’s coverage to include children ages six to 11.” We celebrate this news with our CF community in Saskatchewan who worked tirelessly for this day.”
Add Comment